Aytu BioPharma (AYTU) Fundamental Analysis: Revenue, Earnings & Valuation

8.07 / 10

Outperform

Fundamentally, AYTU rates Outperform with an 8.1/10 score. Inventory turnover (1.74) and cost‑of‑sales ratio (30.96%) are strong, as is interest coverage (35.1) and asset‑MV advantage. Weaknesses include high current‑liabilities ratio (59.9%) and modest revenue growth, yet overall quality remains high.

Analysis Checks(5/10)

Revenue-MV

Value1.26

Score3/3

Weight36.84%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value1.84

Score1/3

Weight-1.44%

1M Return-0.38%

Inventory turnover ratio

Value1.74

Score3/3

Weight-3.62%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value59.94

Score1/3

Weight-5.88%

1M Return-1.69%

PB-ROE

Value-0.93

Score1/3

Weight29.77%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value2.62

Score0/3

Weight-16.00%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.27%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value1.84

Score1/3

Weight-1.13%

1M Return-0.30%

Cost of sales ratio (%)

Value30.96

Score3/3

Weight1.07%

1M Return0.26%

Asset-MV

Value-0.55

Score3/3

Weight64.67%

1M Return11.61%

Is AYTU fundamentally strong?

AYTU scores 8.07/10 on fundamentals and holds a Discounted valuation at present. Backed by its -51.97% ROE, -39.02% net margin, -1.16 P/E ratio, 2.00 P/B ratio, and -252.58% earnings growth, these metrics solidify its Outperform investment rating.